Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 9;40(26):3516-3527.
doi: 10.1016/j.vaccine.2022.04.069. Epub 2022 May 2.

Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization

Affiliations

Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization

Daniel R Feikin et al. Vaccine. .

Abstract

Vaccine effectiveness is lower and wanes faster against infection and symptomatic disease caused by the omicron variant of SARS-CoV-2 than was observed with previous variants. Vaccine effectiveness against severe omicron disease, on average, is higher, but has shown variability, including rapid apparent waning, in some studies. Assessing vaccine effectiveness against omicron severe disease using hospital admission as a measure of severe disease has become more challenging because of omicron's attenuated intrinsic severity and its high prevalence of infection. Many hospital admissions likely occur among people with incidental omicron infection or among those with infection-induced exacerbation of chronic medical conditions. To address this challenge, the World Health Organization held a virtual meeting on March 15, 2022, to review evidence from several studies that assessed Covid-19 vaccine effectiveness against severe omicron disease using several outcome definitions. Data was shown from studies in South Africa, the United States, the United Kingdom and Qatar. Several approaches were proposed that better characterize vaccine protection against severe Covid-19 disease caused by the omicron variant than using hospitalization of omicron-infected persons to define severe disease. Using more specific definitions for severe respiratory Covid-19 disease, such as indicators of respiratory distress (e.g. oxygen requirement, mechanical ventilation, and ICU admission), showed higher vaccine effectiveness than against hospital admission. Second, vaccine effectiveness against progression from omicron infection to hospitalization, or severe disease, also showed higher vaccine protection. These approaches might better characterize vaccine performance against severe Covid-19 disease caused by omicron, as well as future variants that evade humoral immunity, than using hospitalization with omicron infection as an indicator of severe disease.

Keywords: COVID-19; Omicron variant; Vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest Dr. Walter Orenstein is an uncompensated member of the Scientific Advisory Board for Moderna.

References

    1. World Health Organization. Weekly epidemiological update on COVID-19 - 5 April 2022. https://www.who.int/publications/m/item/weekly-epidemiological-update-on... (accessed April 14, 2022).
    1. Keeton R., Tincho M.B., Ngomti A., Baguma R., Benede N., Suzuki A., et al. T cell responses to SARS-CoV-2 spike cross-recognize omicron. Nature. 2022;603(7901):488–492. - PMC - PubMed
    1. International Vaccine Access Center. Results of COVID-19 vaccine effectiveness & impact studies: an ongoing systematic review, methods. https://view-hub.org/sites/default/files/2022-04/COVID19_VE_and_Impact_L... (accessed April 19, 2022).
    1. Feikin D.R., Higdon M.M., Abu-Raddad L.J., Andrews N., Araos R., Goldberg Y., et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. The Lancet. 2022;399(10328):924–944. - PMC - PubMed
    1. Young-Xu Y. Effectiveness of mRNA COVID-19 Vaccines against omicron among Veterans. medRxiv 2022; published online Mar 13. https://doi.org/10.1101/2022.01.15.22269360 (preprint).

Substances

Supplementary concepts